D. VanDevanter

发表

Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens

J. Lipuma, Lisa A. Carmody, M. Mahboubi, 2015, Journal of Clinical Microbiology.

Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells.

D. V. Von Hoff, D. VanDevanter, B. Forseth, 1990, The Journal of clinical investigation.

Expanding access to CFTR modulators for rare mutations: The utility of n-of-1 trials.

A. Magaret, N. Mayer-Hamblett, D. VanDevanter, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The Pseudomonas aeruginosa genome How do we use it to develop strategies for the treatment of patients with cystic fibrosis and Pseudomonas infections?

A. Erwin, D. VanDevanter, 2002, Current opinion in pulmonary medicine.

Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.

N. Mayer-Hamblett, D. VanDevanter, 2020, Trends in molecular medicine.

Finding the relevance of antimicrobial stewardship for cystic fibrosis.

L. Saiman, S. McColley, A. Holmes, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review.

V. Waters, M. Tunney, J. Elborn, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities

P. Flume, D. Nichols, N. Mayer-Hamblett, 2019, Annals of the American Thoracic Society.

Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices.

P. Burgel, A. Holmes, V. Waters, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Defining antimicrobial resistance in cystic fibrosis.

P. Gilligan, V. Waters, J. Lipuma, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Cystic fibrosis: definition, severity and impact of pulmonary exacerbations

P. Flume, D. VanDevanter, 2017 .

Levofloxacin Inhalation Solution ( APT-1026 ) in Stable Cystic Fibrosis Patients

R. Fischer, E. Kerem, S. Aaron, 2017 .

Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies

N. Mayer-Hamblett, D. VanDevanter, 2017, Current opinion in pulmonary medicine.

Anti-Infective Therapies in Cystic Fibrosis

P. Flume, D. VanDevanter, 2017 .

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis

M. Boyle, N. Mayer-Hamblett, D. VanDevanter, 2016, Thorax.

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.

M. Konstan, D. VanDevanter, E. Dasenbrook, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Clinical applications of pulmonary delivery of antibiotics.

P. Flume, D. VanDevanter, 2015, Advanced drug delivery reviews.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis.

F. Accurso, B. Ramsey, M. Konstan, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review

D. VanDevanter, D. Geller, 2011, Medical devices.

Trends in the use of routine therapies in cystic fibrosis: 1995–2005

W. Morgan, M. Konstan, D. Pasta, 2010, Pediatric pulmonology.

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

L. Lester, A. Colin, B. Nickerson, 2004, Pediatric pulmonology.

Anti‐PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection

F. Accurso, M. Konstan, C. Milla, 2014, Pediatric pulmonology.

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.

L. Saiman, P. Gilligan, V. Waters, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

D. Sanders, C. Goss, N. West, 2018, Contemporary clinical trials.

Retracing changes in cystic fibrosis understanding and management over the past twenty years.

F. Ratjen, D. VanDevanter, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Antimicrobial resistance: Concerns of healthcare providers and people with CF.

L. Saiman, P. Dřevínek, V. Waters, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.

F. Accurso, M. Konstan, J. Burns, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Decline in lung function does not predict future decline in lung function in cystic fibrosis patients

M. Rosenfeld, E. Elkin, W. Morgan, 2015, Pediatric pulmonology.

Design and powering of cystic fibrosis clinical trials using rate of FEV(1) decline as an efficacy endpoint.

M. Konstan, D. Pasta, D. VanDevanter, 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo.

D. V. Von Hoff, E. Douglass, D. VanDevanter, 1990, Journal of the National Cancer Institute.

Pure chromosome-specific PCR libraries from single sorted chromosomes.

J. Aten, P. Rabinovitch, C. Behler, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Microbial diversity in the cystic fibrosis airways: where is thy sting?

J. Lipuma, D. VanDevanter, 2012, Future microbiology.

Recombination between separate MYC amplification structures in COLO320 cells

D. VanDevanter, G. Yirdaw, Getachew Yirdaw, 1993, Genes, chromosomes & cancer.

Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.

J. Lipuma, R. Simon, K. Opron, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response

P. Flume, D. VanDevanter, N. West, 2021, Journal of Cystic Fibrosis.

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).

E. Kerem, M. Konstan, I. Sermet-Gaudelus, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.

J. Chalmers, I. Gonda, D. Cipolla, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis.

M. Konstan, S. Heltshe, J. Hilliard, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Association of High‐Dose Ibuprofen Use, Lung Function Decline, and Long‐Term Survival in Children with Cystic Fibrosis

G. Sawicki, W. Morgan, M. Konstan, 2018, Annals of the American Thoracic Society.

Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change

W. Morgan, M. Konstan, D. Pasta, 2018, Pediatric pulmonology.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

D. Sanders, R. Gibson, C. Goss, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis.

D. Sanders, R. Gibson, C. Goss, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function.

W. Morgan, M. Konstan, D. Pasta, 2016, The Journal of pediatrics.

Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European Cystic Fibrosis Patient Registry, 2007-2009.

D. Pasta, D. VanDevanter, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Short Communication Evidence of diminished FEV 1 and FVC in 6-year-olds followed in the European cystic fibrosis patient registry, 2007-2009

D. Pasta, D. VanDevanter, 2013 .

The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations.

L. Hoffman, R. Gibson, K. Whitlock, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients.

J. Burns, N. Mayer-Hamblett, D. VanDevanter, 2015, Journal of the Pediatric Infectious Diseases Society.

Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?

A. Smyth, P. Flume, D. VanDevanter, 2011, Respiratory medicine.

How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?

D. VanDevanter, J. V. Van Dalfsen, 2005, Pediatric pulmonology.

Association of Inhaled Antibiotics in Addition to Standard IV Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.

L. Hoffman, R. Gibson, M. Rosenfeld, 2020, Annals of the American Thoracic Society.

Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations

L. Hoffman, R. Gibson, M. Rosenfeld, 2020 .

Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.

K. Shedden, J. Lipuma, R. Simon, 2019, Annals of the American Thoracic Society.

The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.

L. Caverly, D. VanDevanter, 2022, Journal of the Pediatric Infectious Diseases Society.

Characterizing aggressiveness and predicting future progression of CF lung disease.

M. Konstan, D. VanDevanter, J. Wagener, 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Unusual expression of mRNA typical of Philadelphia positive acute lymphoblastic leukemia detected in chronic myeloid leukemia

J. Reems, E. Bryant, D. VanDevanter, 1996, American journal of hematology.

Loss of DNA-membrane interactions and cessation of DNA synthesis in myeloperoxidase-treated Escherichia coli.

H. Rosen, J. Orman, D. VanDevanter, 1990, Proceedings of the National Academy of Sciences of the United States of America.

BMI fails to identify poor nutritional status in stunted children with CF.

W. Morgan, M. Konstan, D. Pasta, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study.

K. Odem-Davis, N. Mayer-Hamblett, D. VanDevanter, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.

Karen L. Robinson, C. Castellani, K. Raraigh, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.

N. Morris, M. Konstan, P. Flume, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

J. Elborn, P. Flume, D. VanDevanter, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Building global development strategies for cf therapeutics during a transitional cftr modulator era.

C. Goss, P. Dřevínek, S. Donaldson, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.

M. Konstan, S. Rowe, E. Zemanick, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The challenges of maintaining momentum in CF drug development and approval - Commentary.

P. Flume, D. VanDevanter, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer.

T. Standaert, A. Montgomery, D. VanDevanter, 2000, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis.

J. Emerson, R. Gibson, M. Rosenfeld, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes

P. Flume, D. VanDevanter, 2020, European Respiratory Journal.

Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis

W. Morgan, M. Konstan, D. Pasta, 2017, Annals of the American Thoracic Society.

Differential Effects of Myeloperoxidase-Derived Oxidants on Escherichia coli DNA Replication

J. Hughes, H. Rosen, D. VanDevanter, 1998, Infection and Immunity.

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

Clifton E. Barry, William R. Baker, D. Sherman, 2000, Nature.

Detection and analysis of diverse herpesviral species by consensus primer PCR

T. Rose, P. Warrener, R. Garber, 1996, Journal of clinical microbiology.

Risk factors for rate of decline in FEV1 in adults with cystic fibrosis.

W. Morgan, M. Konstan, D. Pasta, 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment.

P. Hodgkins, D. VanDevanter, A. O’sullivan, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization

E. Bryant, D. VanDevanter, J. Kirk, 1994, Genes, chromosomes & cancer.

Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation

P. Flume, D. VanDevanter, M. Skalland, 2021, Journal of Cystic Fibrosis.

Decade-long bacterial community dynamics in cystic fibrosis airways

Susan Murray, Patrick D. Schloss, Jun Z. Li, 2012, Proceedings of the National Academy of Sciences.

Trisomy 8 in primary esthesioneuroblastoma.

M. McNutt, F. Luthardt, D. VanDevanter, 1991, Cancer genetics and cytogenetics.

CFTR modulator theratyping: Current status, gaps and future directions.

J. Wallenburg, J. Clancy, J. Nick, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Cloning of the LamA3 gene encoding the alpha 3 chain of the adhesive ligand epiligrin. Expression in wound repair.

W. Carter, R. Tizard, D. VanDevanter, 1994, The Journal of biological chemistry.

Electrophoretic isolation of extrachromosomal DNA from tumor cells

D. VanDevanter, G. Yirdaw, John C.‐H. Tseng, 1995, Genes, chromosomes & cancer.

Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations.

D. Sanders, D. Patrick, N. West, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment.

D. Sanders, C. Goss, N. West, 2021, American journal of respiratory and critical care medicine.

Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations

W. Morgan, M. Konstan, D. Pasta, 2017, Annals of the American Thoracic Society.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

D. Sanders, C. Goss, J. Nick, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.

N. Morris, M. Konstan, D. VanDevanter, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.

M. Konstan, D. Pasta, D. VanDevanter, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2013, Pediatric pulmonology.

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint.

W. Morgan, M. Konstan, D. Pasta, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

M. O'riordan, M. Konstan, J. Blumer, 2010, Respiratory research.

The march towards CFTR modulator access for all people with CF: The end of the beginning.

D. VanDevanter, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Antipseudomonal treatment decisions during CF exacerbation management.

P. Flume, D. VanDevanter, M. Skalland, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation.

M. Boyle, N. Mayer-Hamblett, D. VanDevanter, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Antibiotic treatment of signs and symptoms of pulmonary exacerbations: A comparison by care site

M. Rosenfeld, G. Sawicki, W. Morgan, 2015, Pediatric pulmonology.

Epidemiologic Study of Cystic Fibrosis: 25 years of observational research

W. Morgan, M. Konstan, D. Pasta, 2021, Pediatric pulmonology.

CFTR modulators and pregnancy: Our work has only just begun.

C. Goss, D. VanDevanter, 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.

M. Konstan, D. VanDevanter, 2012, Clinical investigation.

Comparison of FEV1 reference equations for evaluating a cystic fibrosis therapeutic intervention

W. Morgan, M. Konstan, D. Pasta, 2017, Pediatric pulmonology.

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis

M. Rogers, J. Lipuma, R. Simon, 2018, PloS one.

Another step in the journey: From CFTR mutation to sweat chloride concentration to survival.

N. Mayer-Hamblett, D. VanDevanter, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Pulmonary outcome prediction (POP) tools for cystic fibrosis patients

E. Elkin, W. Morgan, M. Konstan, 2010, Pediatric pulmonology.

Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005

W. Morgan, M. Konstan, L. Rasouliyan, 2008, Pediatric pulmonology.

37 Microbiologic changes observed over 6 months in a randomized, open-label comparison of inhaled levofloxacin and inhaled tobramycin in persons with cystic fibrosis and chronic P. aeruginosa (Pa) airway infection

J. Lipuma, P. Flume, D. VanDevanter, 2016 .

38 History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin

J. Elborn, P. Flume, D. VanDevanter, 2016 .

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005.

E. Elkin, W. Morgan, M. Konstan, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Chapter 2 Epidemiology of cystic fibrosis lung disease progression in adolescence

D. VanDevanter, 2013 .

Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.

D. Sanders, S. Heltshe, D. VanDevanter, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

W. Morgan, M. Konstan, D. Pasta, 2019, Pediatric pulmonology.

The challenge of improving outcomes for patients with CF sinonasal disease.

K. Southern, D. VanDevanter, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment.

C. Goss, P. Flume, D. VanDevanter, 2020, Journal of Cystic Fibrosis.

First bacterial infection as an alternative clinical end point for regulatory approval of agents targeting the primary cystic fibrosis defect.

D. VanDevanter, 2005, The Journal of pediatrics.

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

M. Konstan, J. Mcintosh, D. VanDevanter, 2020, Journal of Cystic Fibrosis.

Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis.

M. Ballmann, P. Flume, D. VanDevanter, 2011, Respiratory medicine.

510 Prevalence and clinical impact of respiratory viral infections in the Standardized Treatment of Pulmonary Exacerbations 2 Study

L. Caverly, L. Kalikin, D. VanDevanter, 2022, Journal of Cystic Fibrosis.

Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.

K. Odem-Davis, N. Mayer-Hamblett, D. VanDevanter, 2023, Journal of Cystic Fibrosis.

The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans?

P. Flume, D. VanDevanter, 2017, Annals of Internal Medicine..

What shall we learn from TEACH?

J. Lipuma, D. VanDevanter, 2021, Thorax.

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.

R. Fischer, E. Kerem, S. Aaron, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005

W. Morgan, M. Konstan, L. Rasouliyan, 2008, Pediatric pulmonology.

EPS7.7 Microbiologic changes in CF patients with chronic P. aeruginosa airway infection after 6 cycles of inhaled levofloxacin

J. Elborn, P. Flume, D. VanDevanter, 2017 .

Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies.

J. Lipuma, S. Heltshe, D. VanDevanter, 2016, Annals of the American Thoracic Society.